Optimizing Investments in Malaria Treatment and Diagnosis

See allHide authors and affiliations

Science  02 Nov 2012:
Vol. 338, Issue 6107, pp. 612-614
DOI: 10.1126/science.1229045

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The Roll Back Malaria (RBM) Partnership has set an ambitious target of achieving near zero deaths from malaria by 2015 (1). Scale-up of insecticide-treated nets, indoor residual spraying of insecticide, and increased access to treatment with artemisinin-based combination therapies (ACTs) over the past decade have led to reductions in malaria incidence of more than 50% in 43 countries, including 8 in Africa (2). However, as an estimated 655,000 malaria deaths still occurred in 2010 (2), with the great majority in sub-Saharan Africa, substantial challenges remain.